Immunological Priming Boosts 177Lu-PSMA-617 Efficacy in mCRPC: SNMMI 2026 Study Insights
At the 2026 SNMMI meeting, a retrospective cohort study revealed immunological priming enhanced 177Lu-PSMA-617 efficacy in mCRPC, sparking market interest in prostate cancer therapeutics. The findings may influence investment flows ... Read More